Skip to main content
. Author manuscript; available in PMC: 2016 May 17.
Published in final edited form as: Sci Signal. 2015 Nov 17;8(403):ra116. doi: 10.1126/scisignal.aad5111

Figure 4. Increased abundance of 4EBP1 is required to maintain resistance to PI3K pathway inhibitors and is a marker of resistant cells in human prostate cancer.

Figure 4

(A) Representative Western blot analysis from 2 experiments for PTEN and 4EBP1 in PTEN KD LHS PrEC clones and control LHS cells. (B) Analysis of apoptosis by propidium iodide/annexin V staining in PTEN KD LHS PrEC cells after 12 hours’ exposure to MLN0128 or vehicle (–MLN0128). (n = 5 replicates in two independent experiments, *P<0.0001, **P = 0.04, t-test). (C) Representative Western blot of 4EBP1 in PTEN KD LHS PrEC cells with and without si4EBP1. (D) Analysis of apoptosis by propidium iodide/annexin V staining of PTEN-KD LHS PrEC cells after transfection with a 4EBP1-targeted siRNA pool (n = 8 replicates in two independent experiments *P<0.0001, **P = 0.005, t-test). (E) Representative autoradiograph (left) and quantification of S35-methionine incorporation assays in PTEN KD LHS PrEC clones upon silencing 4EBP1. (n = 3 independent experiments, *P < 0.05, ANOVA). (F) Representative cap-binding assay in PTEN knockdown LHS clones upon silencing 4EBP1. n.s. = not statistically significant. Data are mean ± S.E.M.